First Trust Nasdaq Pharmaceuticals ETF (FTXH)
| Assets | $16.78M |
| NAV | $25.82 |
| Expense Ratio | 0.60% |
| PE Ratio | 24.06 |
| Shares Out | 650,000 |
| Dividend (ttm) | $0.23 |
| Dividend Yield | 0.90% |
| Ex-Dividend Date | Sep 23, 2021 |
| 1-Year Return | - |
| Volume | 5,000 |
| Open | 26.06 |
| Previous Close | 25.75 |
| Day's Range | 25.81 - 26.10 |
| 52-Week Low | 22.71 |
| 52-Week High | 27.01 |
| Beta | 0.90 |
| Holdings | 29 |
| Inception Date | Sep 20, 2016 |
About FTXH
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.
Top 10 Holdings
59.55% of assets| Name | Symbol | Weight |
|---|---|---|
| Prestige Consumer Healthcare | PBH | 8.38% |
| Merck | MRK | 8.38% |
| Johnson & Johnson | JNJ | 7.63% |
| Pfizer | PFE | 7.47% |
| AbbVie | ABBV | 7.19% |
| Horizon Therapeutics | HZNP | 4.31% |
| Alkermes | ALKS | 4.21% |
| Catalent | CTLT | 4.08% |
| Zoetis | ZTS | 4.04% |
| Gilead Sciences | GILD | 3.86% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2021 | $0.0393 | Sep 30, 2021 |
| Jun 24, 2021 | $0.0533 | Jun 30, 2021 |
| Mar 25, 2021 | $0.0771 | Mar 31, 2021 |
| Dec 24, 2020 | $0.0644 | Dec 31, 2020 |
| Sep 24, 2020 | $0.0428 | Sep 30, 2020 |
| Jun 25, 2020 | $0.0463 | Jun 30, 2020 |
News
Pharma ETFs Gain on Q2 Earnings
Many industry bigwigs reported solid results with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Q1 Earnings
The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.
ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Pharma ETFs in Focus Post Q4 Earnings
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
Q3 Earnings Fail to Impress Pharma ETFs
The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.
Nasdaq Pharmaceuticals ETF (FTXH) Hits a 52-Week High
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?
Pharma ETFs Soar on Robust Q2 Earnings
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
ETF Spotlight: Pharmaceuticals driven higher by Pfizer
CNBC'S Morgan Brennan takes a look at pharmaceutical as Pfizer's positive vaccine news has led the sector higher.
Pharma ETFs Gain on Healthy Q4 Earnings
Strong results led to solid trading in pharma ETFs over the past week.
Pharma ETFs Set to Benefit Post Strong Q3 Earnings
Robust results led to solid trading in pharma ETFs in a month.
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?
Despite robust results, pharma ETFs have been trending downward in a month.
Pharma ETFs Down Despite Solid Q1 Results
Despite such robust results, pharma ETFs have been trending downward in a month.